MX2007005525A - Tratamiento terapeutico de resorcion ose acelerada. - Google Patents

Tratamiento terapeutico de resorcion ose acelerada.

Info

Publication number
MX2007005525A
MX2007005525A MX2007005525A MX2007005525A MX2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A MX 2007005525 A MX2007005525 A MX 2007005525A
Authority
MX
Mexico
Prior art keywords
bone resorption
accelerated bone
therapeutic treatment
pharmaceutical composition
treatment
Prior art date
Application number
MX2007005525A
Other languages
English (en)
Spanish (es)
Inventor
Pnina Fishman
Lea Madi
Sara Bar-Yehuda
Original Assignee
Can Fite Biopharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Can Fite Biopharma Ltd filed Critical Can Fite Biopharma Ltd
Publication of MX2007005525A publication Critical patent/MX2007005525A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MX2007005525A 2004-11-08 2005-11-08 Tratamiento terapeutico de resorcion ose acelerada. MX2007005525A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62556404P 2004-11-08 2004-11-08
PCT/IL2005/001166 WO2006048884A1 (en) 2004-11-08 2005-11-08 Therapeutic treatment of accelerated bone resorption

Publications (1)

Publication Number Publication Date
MX2007005525A true MX2007005525A (es) 2007-07-05

Family

ID=36001028

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007005525A MX2007005525A (es) 2004-11-08 2005-11-08 Tratamiento terapeutico de resorcion ose acelerada.

Country Status (9)

Country Link
EP (1) EP1811982A1 (ko)
JP (1) JP2008519029A (ko)
KR (1) KR20070085839A (ko)
CN (1) CN101072554A (ko)
AU (1) AU2005302090A1 (ko)
BR (1) BRPI0517639A (ko)
CA (1) CA2586845A1 (ko)
MX (1) MX2007005525A (ko)
WO (1) WO2006048884A1 (ko)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006321165B2 (en) * 2005-11-30 2010-04-22 Can-Fite Biopharma Ltd. Use of A3 adenosine receptor agonist in osteoarthritis treatment
WO2008111082A1 (en) 2007-03-14 2008-09-18 Can-Fite Biopharma Ltd. Process for the synthesis of ib-meca
US8183225B2 (en) * 2007-11-08 2012-05-22 New York University Inhibition of bone resorption using medical implants containing adenosine receptor antagonists
AU2010250759B2 (en) * 2009-05-17 2013-03-14 Can-Fite Biopharma Ltd. A3 adenosine receptor agonists for the reduction of intraocular pressure
MX356509B (es) 2011-12-22 2018-05-30 Alios Biopharma Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos.
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
USRE48171E1 (en) 2012-03-21 2020-08-25 Janssen Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000072799A2 (en) * 1999-05-27 2000-12-07 The University Of Virginia Patent Foundation Method and compositions for treating the inflammatory response
IL133680A0 (en) * 1999-09-10 2001-04-30 Can Fite Technologies Ltd Pharmaceutical compositions comprising an adenosine receptor agonist or antagonist
US7141553B2 (en) * 2002-11-19 2006-11-28 Can-Fite Biopharma Ltd. Israel A3AR agonists for the treatment of inflammatory arthritis
GB0305150D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Use of therapeutic compounds
EA011099B1 (ru) * 2004-03-05 2008-12-30 Кембридж Байотекнолоджи Лимитед Терапевтические соединения

Also Published As

Publication number Publication date
BRPI0517639A (pt) 2008-10-14
CN101072554A (zh) 2007-11-14
AU2005302090A1 (en) 2006-05-11
JP2008519029A (ja) 2008-06-05
KR20070085839A (ko) 2007-08-27
EP1811982A1 (en) 2007-08-01
CA2586845A1 (en) 2006-05-11
WO2006048884A1 (en) 2006-05-11

Similar Documents

Publication Publication Date Title
BRPI0518483A2 (pt) composiÇço compreendendo uma matriz ou revestimento de liberaÇço controlada e um antagonista de receptor de nmda, mÉtodo para administraÇço de tal antagonista de nmda a um paciente
MX2007005525A (es) Tratamiento terapeutico de resorcion ose acelerada.
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
SG171649A1 (en) Dpp iv inhibitor formulations
SG170828A1 (en) Deazapurines useful as inhibitors of janus kinases
SI1735278T1 (sl) Agenti histamin h receptorja priprava in terapevtska uporaba
TW200633980A (en) Pyridones useful as inhibitors of kinases
MEP27408A (en) Use of gpr119 receptor agonists for increasing bone mass and for treating osteoporosis, and combination therapy relating thereto
EA200800162A1 (ru) Новые фармацевтические композиции с замедленным высвобождением и способы их получения
HK1138276A1 (en) Azetidine analogues of nucleosidase and phosphorylase inhibitors
AU2006342119A8 (en) Soluble human M-CSF receptor and uses thereof
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
BRPI0509074A (pt) composições farmacêuticas compreendendo agonistas do receptor da tiróide
NO20076219L (no) Farmasoytisk formulering med apomorfin for bukkal administrering
IL179206A0 (en) Pyrrolylpyrimidine derivatives and pharmaceutical compositions containing the same
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
EP1784173A4 (en) PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING METABOLIC BONE DISEASES CONTAINING ALPHA-ARYLMETHOXYACRYLATE DERIVATIVES
HK1112228A1 (en) Substituted azachinzolines having an antiviral action
MXPA04011835A (es) Tratamiento de combinacion para la depresion y ansiedad.
HK1121670A1 (en) Preparation and composition of inter-alpha inhibitor proteins from human plasma for therapeutic use
EP1213031A3 (en) Combination treatment for depression, anxiety and psychosis comprising an antidepressant and/or anxiolytic and a D4 receptor antagonist
TW200833710A (en) Treatment for spinal muscular atrophy
TWI256388B (en) Pharmaceutical combination
EP1260221A3 (en) Combination treatment for depression and anxiety
AU2001250722A1 (en) Medicament for the treatment of diseases caused by parasitic protozoa

Legal Events

Date Code Title Description
FA Abandonment or withdrawal